Dublin, Nov. 06, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/m9...al_and_usa ) has announced the addition of the "BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor (Anti-TNF), Monoclonal Antibodies (MAbs), Insulins, Interferons, Product Pipelines, Trends, Key Players, Regulations and Strategic Outlook " report to their offering. Biosimilars are highly-similar versions of biological drugs that are indicated for cancer, kidney disorders and a wide range of autoimmune diseases. Originator biologics are the most expensive drugs in the pharmaceutical industry and many of them cost nearly $100,000 per patient per year. These expensive biologics impose a heavy financial burden on patients and healthcare systems, limiting easy access and optimal care. Patent protection for some of the biologics has already expired and many more are to lose patent rights between now and 2020. This has given an opportunity to biotechnology companies to develop and market biosimilars with a cost benefit of about 20% to 30%. In order to gain a slice of the $190 billion worth of biologic's market, many biotechnology companies have ventured into the biosimilar sector bringing out less-expensive copies of reference biologics. Biosimilars have been in the E.U. market since 2006 and less-regulated markets such as China, India, and South Korea have a number of biosimilars in their domestic markets. After a long delay, finally, the FDA took a historic decision to approve the first biosimilar Zarxio from Sandoz on March 6, 2015. The coming years will witness the flooding of large number of biosimilars into the U.S., which happens to be the largest market for biopharmaceuticals. This report provides a comprehensive overview of the size of biosimilars' market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. On total, about 44 biosimilars are available in the global market and currently the E.U. is the major market with 19 approved biosimilars in use. A significant number of biosimilars are available in the markets of China, India, South Korea and Latin America. Biosimilars from these emerging countries are approved by a less-stringent approval pathway and therefore, the commercialization of their products is mostly confined to the domestic markets. The report describes how the long-awaited FDA approval of Zarxio from Sandoz (biosimilar for Amgen's Neupogen) in March 2015 is to transform the otherwise nascent market. The report includes:
- An overview of biosimilars that includes differences between biologics; biosimilars and generics, definition of biosimilars by different agencies, barriers in developing biosimilars, cost of developing biosimilars. - A summary of regulatory pathways in various geographic regions. - Development of biosimilars in Europe, China, India, South Korea, Latin America and the sudden spurt in the development of biosimilars in the U.S. - A list of biosimilar developers in different geographic locations. - An overview of biobetters that includes regulatory considerations, differences between biosimilars and biobetters, various biobetters that are in developmental stages, and the companies with the largest biobetter pipeline. - An overview of approved biosimilars in the E.U., U.S., India, South Korea and Latin America. - The market impact of biosimilars on their reference biologics such as Epogen, Humira, Remicade, Neupogen, Neulasta, Enbrel, Rituxan, Herceptin, Avastin and Lantus through 2021. - The top ten biologics on the focus of biosimilar developers. - The five major classes of biologics and their biosimilar counterparts. - The current landscape of originators of biosimilars. - Global market for biologics by region, through 2021. - Global market for biologics by indication, through 2021. - Global market for biologics by drug class, through 2021. - Global market for biosimilars by region, through 2021. - Global market for biosimilars by indication, through 2021. - Global market for biosimilars by drug class, through 2021. - Profiles of 95 biosimilar developers, their products in the market and their product pipeline. - A newsletter in the appendix gives the latest news of biosimilar sector as of February 2015. Key Topics Covered: 1.0 Introduction 2.0 Biosimilars: A Brief Overview 3.0 Regulations for Biosimilars: An Overview 4.0 Development of Biosimilars: An Overview 5.0 Biobetters: An Overview 6.0 The Approved Biosimilars: An Overview 7.0 The Impact of Biosimilars on Originators: An overview 8.0 Top Ten Biologics on the Focus of Biosimilar Developers 9.0 Five Major Classes of Originator Biologics and their Market Performance 10.0 The Landscape of the Originators of Biosimilars 11.0 A Brief Analysis of Market for Biologics 12.0 Market for Biosimilars: An Overview 13.0 Selected Company Profiles - 3SBio - AET BioTech - Abzena - Actavis - Alvogen - Amega Biotech - Amgen - Anhui Anke Biotechnology (Group) Co., Ltd. - Apotex - Avesthagen Ltd. - Baxter International Inc. - Beijing Four Rings Biopharmaceutical Co., Ltd. - Bharat Biotech International Ltd. - Binovis SA - BioXpress Therapeutics SA - Biocon Ltd. - Biogen Inc. - Biopartners GmbH - Biosidus SA - Biotechnol AS - Bioton Spolka AKcyjna - Bioviz Technologies Pvt, Ltd. - Boehringer Ingelheim GmbH - Bolder BioTechnology Inc. - CJSC Biocad - CT Arzneimittel GmbH - Cadilla Pharmaceuticals Ltd. - Celltrion Inc. - Cerbios-Pharma SA - Cipla Ltd. - Ckd Bio Corporation - Claris Lifesciences Ltd. - Coherus Biosciences Inc. - Dawoong Pharmaceutical Co., Ltd. - Dong-A Socio Holdings Co., Ltd. - Dr. Reddy's Laboratories Ltd. - Eli Lilly & Co. - Emcure Pharmaceutical Ltd. - Epirus Biopharmaceuticals Inc. - Finox AG - Fujifilm Diosynth Biotechnologies - Gan & Lee Pharmaceuticals Ltd. - GeneScience Pharmaceuticals Co., Ltd. - Genexine Co. Ltd. - Gennova Biopharmaceuticals Ltd. - Genor BioPharma Co., Ltd. - Glenmark Pharmaceuticals Ltd. - Glycotope GmbH - Green Cross Corporation - HanAll BioPharma Co., Ltd. - Hanwha Chemical Corporation - Harvest Moon Pharmaceuticals USA Inc. - Hetero Drugs Ltd. - Hexal Ag - Hospira Inc. - ISU Abxis Co., Ltd. - Innovent Biologics Inc. - Intas Pharmaceuticals Ltd. - Kyowa Hakko Kirin Pharma Inc. - LG Life Sciences Co. Ltd. - Lupin Ltd. - MJ Biopharm Pvt., Ltd. - Mabion SA - MacroGenics Inc. - Medice Arzneimittel Putter GmbH & Co. KG - Merck & Co., Inc. - Merck Serono - Mochida Pharmaceutical Co., Ltd. - Momenta Pharmaceuticals Inc. - Mycenax Biotech Inc. - Mylan NV - Nippon Kayaku Co., Ltd. - Oncobiologics Inc. - Pfizer Inc. - Pharma Praxis - PlantForm Corporation - Polypharma SA - Probiomed SA. De C.V. - Protalix BioTherapeutics Inc. - Ranbaxy Laboratories (Sun Pharma) - Ratiopharm GmbH - Reliance Life Sciences Pvt. Ltd. - Samsung Bioepis Co., Ltd. - Sandoz Inc. - Shanghai CP Guojian Pharmaceutical Co., Ltd. - Shantha Biotechnics Ltd. - Shenzhein Kexin Biotech Co., Ltd. - Stada Arzneimittel AG - Synthon BV - Teva Pharmaceutical Industries Ltd. - USV Ltd. - Wockhardt Ltd. - Xencor Inc. - Xiamen Amoytop Biotech Co., Ltd. - mAbxience For more information visit http://www.researchandmarkets.com/research/m9...al_and_usa
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Biosimilars and Biosuperiors
